Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sarepta reports robust earnings, poised for gene therapy milestone

Sarepta Therapeutics delivered strong financial performance in Q4 2022, driven by revenue growth and positive market reception of its RNA-based PMO therapies.
While facing challenges in managing expenses and navigating regulatory uncertainties, the company is strategically positioned to capitalize on growth opportunities in gene therapy and market expansion.
By focusing on innovation, operational readiness, and market access, Sarepta aims to secure a leading position in Duchenne muscular dystrophy treatment and drive sustainable revenue growth.

Sarepta Therapeutics exceeds Q1 revenue expectations, poised for growth

Sarepta Therapeutics delivered strong financial results in Q1 2023, exceeding expectations and showcasing market confidence in their growth trajectory.
The company's proactive approach to patient access, payer engagement, and therapy development highlights their commitment to addressing unmet medical needs and advancing innovative treatments.
While facing pricing challenges and regulatory decisions, Sarepta's focus on research, partnerships, and therapy expansion presents opportunities for sustained growth and impact.
With a robust pipeline, positive payer discussions, and ongoing studies, Sarepta is poised to make a significant difference in treating rare diseases and improving patient outcomes.

Sarepta Therapeutics excels in Q2 with ELEVIDYS approval and patient-focused strategies

Sarepta Therapeutics demonstrated strong performance in Q2 2023 with positive revenue growth and progress in clinical studies and commercial activities.
Despite challenges in administrative processes and label expansion, the company's focus on patient care and operational efficiency remains a key strength.
Opportunities lie in broadening therapy access, addressing limitations, and streamlining patient access post label expansion for enhanced market reach and treatment efficiency.

Sarepta Therapeutics excels in Q3 earnings, eyes label expansion

Sarepta Therapeutics delivered robust financial performance in Q3 2023, driven by the success of ELEVIDYS and PMOs. Despite challenges in regulatory processes and market competition, the company's strategic focus on label expansion and patient access presents significant growth opportunities.

Sarepta Therapeutics reports robust Q4 earnings and targets pipeline expansion

Sarepta Therapeutics delivered strong financial results in Q4 2023, showcasing revenue growth and profitability. Despite facing challenges such as potential margin declines and clarity issues, the company is well-positioned to capitalize on opportunities for pipeline advancement and expansion.

Sarepta Therapeutics excels in Q1 earnings, eyes label expansions

Sarepta Therapeutics delivered strong financial performance in Q1 2024, driven by robust revenue growth and steady demand for key products like ELEVIDYS.
The company's strategic focus on label expansions and innovative R&D efforts positions it well for future success in addressing unmet medical needs and driving market expansion.
While facing challenges in patient demographics and operational readiness, Sarepta remains well-capitalized and poised to capitalize on upcoming opportunities for growth and market leadership.

Sarepta Therapeutics reports robust Q2 revenue and eyes therapy expansion

Sarepta Therapeutics is experiencing strong revenue growth driven by ELEVIDYS, with a focus on patient outcomes and manufacturing capacity. Challenges include addressing bottlenecks and patient prioritization, while opportunities exist in therapy development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Roche Holding AG

Sarepta: Roche Partnership After The FDA's Turnaround Forms The Basis For A $158.59 Near-Term Price Target

Sarepta Therapeutics: Continued Progress In Duchenne MD

Sarepta Therapeutics Inc (NASDAQ: SRPT) has entered a partnership with Roche (OTC: RHHBY) to commercialize SRP-9001, its gene therapy for Duchenne Muscular Dystrophy, outside of the U.S.

Analysts: Roche Partnership Derisks Sarepta Investor Concerns

Sarepta (SRPT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Sarepta (SRPT) Looks Good: Stock Adds 7.5% in Session

Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares made a handy gain to start the week after it announced a licensing agreement with Roche.

Why This Duchenne Muscular Dystropy Deal Could Be Huge

Roche Holdings AG Basel ADR (OTC: RHHBY) said Monday that it has signed a licensing agreement with Sarepta Therapeutics Inc (NASDAQ: SRPT) to acquire the commercial rights to the latter's investigational gene therapy asset SRP-9001 outside of the U.S.

Sarepta, Roche Strike Gene Therapy Licensing Agreement Worth Up To $2.85B

Sarepta (SRPT) grants ex-U.S. marketing rights of its gene therapy DMD candidate, SRP-9001, to Roche for an upfront payment of $1.15 billion.

Sarepta Signs Gene Therapy Agreement With Roche for $1.15B

Roche Holding AG  made its second major gene therapy deal in a year on Monday, spending $1.15 billion to obtain the rights to Sarepta Therapeutics Inc's  investigational drug to treat duchenne muscular dystrophy (DMD) outside the United States.

Roche dives deeper into gene therapy with $1.15 billion Sarepta licensing deal

– Roche obtains the exclusive right to launch and commercialize SRP-9001 outside the United States –

Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001

Alector Inc

Amgen

Fulcrum Therapeutics Inc

Ultragenyx Pharmaceutical

Schnitzer Steel Industries Inc

SAGE Therapeutics

Vertex Pharmaceuticals

Biotech investing is risk-fraught, but for investors who make the right bets, the returns can be staggering.

8 Biotech Stocks Morgan Stanley Recommends For 2020

Sarepta Therapeutics: FDA Approval Reinstalls Confidence In The Pipeline

The FDA's approval of a second Duchenne muscular dystrophy drug brings Sarepta one step closer to market leadership.

FDA's About-Face on Sarepta Drug Lifts Its Stock Out of the Doldrums

Wave Life Sciences stock crashed Monday after the biotech company scrapped development of two Duchenne muscular dystrophy treatments. The decision will benefit rival Sarepta Therapeutics.

Why This Biotech's 50% Plummet Will Undoubtedly Benefit Sarepta

Once Shunned For Marketing Approval, Golodirsen Is Now A Major Win For Sarepta

U.S. health regulators approved a second drug for a debilitating form of muscular dystrophy, a surprise decision after the medication was rejected for safety concerns just four months ago.

In surprise decision, US approves muscular dystrophy drug

Sarepta Therapeutics (SRPT) has good news for SRPT stock investors concerning its treatment for Duchenne muscular dystrophy.
The post Sarepta Therapeutics News: SRPT Stock Skyrockets 36% on FDA Approval of Muscular Dystrophy Drug appeared first on InvestorPlace.

Sarepta Therapeutics News: SRPT Stock Skyrockets 36% on FDA Approval of Muscular Dystrophy Drug

After an earlier rejection, Sarepta Therapeutics Inc (NASDAQ: SRPT)'s Vyondys 53 received FDA approval the second time around, sending the stock sharply higher Friday.

FDA Approves Sarepta's Second DMD Drug, Analyst Projects $500M-Plus Opportunity

Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares jumped on Friday after the firm announced that the U.S.

Sarepta Catches a Big Break With Duchenne Muscular Dystrophy Drug

Shares of Sarepta Therapeutics rocketed Friday after the biotech company's previously rejected Duchenne muscular dystrophy drug nabbed U.S. approval. SRPT stock soared 32%, near 132.60.

Sarepta Rockets After FDA Approves Previously Rejected DMD Drug

CAMBRIDGE, Mass., Dec.  13, 2019  (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has entered into an agreement with funds managed by Pharmakon Advisors, LP, that provides Sarepta with up to $500 million of borrowing capacity in two tranches. The first $250 million (Tranche A) is available shortly after closing in December 2019, with an additional $250 million (Tranche B) available at Sarepta’s option by Dec. 31, 2020, subject to certain conditions. Both tranches are available at a rate of 8.5% annually, payable quarterly. The facility will mature 48 months from the Tranche A closing date. Additional information on the agreement will be set forth in a Form 8-K to be filed by the Company with the Securities and Exchange Commission.

Sarepta Therapeutics Announces $250 Million of Non-Dilutive Senior Secured Loan Financing

Sarepta (SRPT) exon-53 skipping DMD drug, Vyondys 53, gets approval in the United States following a CRL in August.

Sarepta's Vyondys 53 Receives FDA Approval for DMD, Stock Up

Sarepta scored a surprise regulatory win yesterday.

Why Sarepta Therapeutics Stock Is Jumping Today

Sarepta Therapeutics Inc. SRPT, -0.97% shares surged in the extended session Thursday after the genetic medicine company said the Food and Drug Administration approved its muscular dystrophy treatment.

Sarepta stock surges more than 20% as FDA finally OKs muscular dystrophy drug

-- VYONDYS 53 is Sarepta’s second RNA exon-skipping treatment for DMD approved in the U.S. --  -- Commercial distribution of VYONDYS 53 in the U.S. will commence immediately --

Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?

News for Sarepta Therapeutics Stock (SRPT)